FXEmpire
09 Sept 2026, 20:40 UTC · 1d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Compass Pathways released positive 52-week topline data from Part C of its Phase 3 COMP005 trial for its synthetic psilocybin treatment. — Positive Phase 3 trial data is a primary value driver for biotech firms and often precedes regulatory approval.
+0.60Compass Pathways estimates the commercial launch of its treatment-resistant depression product for the first half of 2027. — Providing a concrete commercialization timeline allows investors to model future revenue streams.
+0.40CMPS stock experienced a volume spike to a 23-day high while attempting a breakout above its three-month basing pattern. — High-volume price action suggests strong institutional interest, though the breakout remains unconfirmed technically.
+0.20Which stocks this story touches
Continue reading
5 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
13h ago
